BPS-001 Pre-Clinical Data

Preliminary data has demonstrated that BPS-001 inhibits tumor growth in three prostate cancer xenografts, LNCaP, PC3 and 22RV1; a transgenic, tumor allograft model, TRAMP-C2; and, a triple negative breast cancer xenograft model, MDA MD 231. In addition, our data demonstrated an inhibition of angiogenesis and an increase in apoptosis. The Company is moving forward with clinical development of BPS-001 as an agent against metastatic, castration resistant prostate cancer (mCRPC), as a first indication. With multiple anticancer mechanisms of action, we expect that tumors will be less likely to confer resistance to BPS-001 compared to the currently available androgen receptor inhibitors.